We break down what the research says happens after stopping GLP-1 medications like semaglutide and tirzepatide, including the scale, hunger signals, and key lab changes. We explain the biology behind rebound and why weight regain is predictable physiology rather than a willpower problem.
• GLP-1s as long-term management for obesity and type 2 diabetes, not a cure
• what GLP-1 does in the brain, stomach, and pancreas and what reverses after stopping
• STEP 1 extension numbers showing about two-thirds regain over a year after stopping Wegovy
• meta-analysis findings on average regain after semaglutide or tirzepatide
• why bigger losses often come with bigger rebounds and why regain is typically gradual
• body composition concerns, regain tending to be more fat than muscle
• what happens to A1C, fasting glucose, blood pressure, and cholesterol after discontinuation
• set point, metabolic adaptation, and counter-regulatory appetite signals
• legitimate reasons people stop and why stopping should be a planned transition
You can find us on Instagram, threads. You can send us an in um a voicemail.

Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.

Support the show

Production and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RN

Artwork Rebrand and Avatars:

Vantage Design Works (Vanessa Jones)

Website: https://www.vantagedesignworks.com/

Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qr

Original Artwork Concept: Olivia Pawlowski